SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Primmune Therapeutics, a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 INFLECTION-003 clinical study triggering the release of the second tranche of financing. The financing advances the development of Polvitolimod HCl (also known as PRTX007) as a curative therapy in the neoadjuvant and adjuvant settings for stage III melanoma.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
